Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-25
2011-12-13
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S299000, C514S318000, C544S129000, C546S194000, C546S236000
Reexamination Certificate
active
08076329
ABSTRACT:
The present patent application concerns compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a mono or bicyclic saturated nitrogen-containing ring; their preparation and their use as a H3 receptor ligand for treating e.g. CNS disorders like Alzheimer's disease.
REFERENCES:
patent: 4707487 (1987-11-01), Arrang et al.
patent: 5290790 (1994-03-01), Arrang et al.
patent: 5356916 (1994-10-01), Toyofuku et al.
patent: 5463074 (1995-10-01), Shih et al.
patent: 5486526 (1996-01-01), Durant et al.
patent: 5559113 (1996-09-01), Schwartz et al.
patent: 5578616 (1996-11-01), Aslanian et al.
patent: 5639775 (1997-06-01), Durant et al.
patent: 5663350 (1997-09-01), Durant et al.
patent: 5990317 (1999-11-01), Phillips et al.
patent: 6080871 (2000-06-01), Kalindjian et al.
patent: 6166060 (2000-12-01), Phillips et al.
patent: 6248765 (2001-06-01), Schwartz et al.
patent: 2005/0113435 (2005-05-01), Hancock et al.
patent: 2005/0182045 (2005-08-01), Nagase et al.
patent: 2006/0235049 (2006-10-01), Apodaca et al.
patent: 21 42 563 (1973-05-01), None
patent: 680 960 (1995-11-01), None
patent: 2004262890 (2004-09-01), None
patent: WO-92/15567 (1992-09-01), None
patent: WO-93/12107 (1993-06-01), None
patent: WO-95/06037 (1995-03-01), None
patent: WO-95/11894 (1995-05-01), None
patent: WO-96/40126 (1996-12-01), None
patent: WO-00/06254 (2000-02-01), None
patent: WO-01/19821 (2001-03-01), None
patent: WO-01/74773 (2001-10-01), None
patent: WO-01/74814 (2001-10-01), None
patent: WO-01/74815 (2001-10-01), None
patent: WO 02/12214 (2002-02-01), None
patent: WO-03/097047 (2003-11-01), None
patent: WO 2004/089373 (2004-10-01), None
patent: WO-2005/070900 (2005-08-01), None
patent: WO-2005/077953 (2005-08-01), None
patent: WO-2005/089747 (2005-09-01), None
patent: WO 2006/004937 (2006-01-01), None
patent: WO-2006/004937 (2006-01-01), None
Brittain et al. “Polymorphism in Pharmaceutical Dosage Forms.” Polymorphism in Pharmaceutical Solids XX (Jan. 1999). pp. 235-238, 348-361.
Morissette et al. “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.” Advanced Drug Delivery Reviews 2004, 56, 275-300.
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
Shah et al. Bioorg. Med. Chem. Lett. 12 (2002), pp. 3309-3312.
Faghih et al, “Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands” Nov. 4, 2002, pp. 3077-3079, vol. 12, No. 21, Bioorganic & Medicinal Chemistry Letters, Oxford, Great Britain.
Apelt et al, “Seach for histamine H3 receptor antagonists with combined inhibitory potency at N-Methyltransferase: Ether Derivatives” 2005, pp. 97-106, vol. 60, No. 2, Pharmazie, Die, GOVI Verlag, Eschborn, DE.
Peschke et al, “Cinnamic amides of (S)-2-(aminomethyl)pyrrolidines are potent H3 antagonists”, 2004, pp. 2603-2616, vol. 12, Bioorganic & Medicinal Chemistry.
Hiltmann et al, “Synthese von trans-3,5-Dimethyl-piperidin”, 1971, pp. 213-214, Synthesis.
Arrang et al, “Actions of Betahistine at Histamine Receptors in the Brain”, 1985, pp. 73-84, vol. 111, European Journal of Pharmacology.
Arrang et al, “Phencyclidine blocks histamine H3-receptors in rat brain”, 1988, pp. 31-35, vo. 157, European Journal of Pharmacology.
Clitherow et al, “Novel 1, 2, 4-Oxadiazoles as Potent and Selective Histamine H3Receptor Antagonists”, 1996, pp. 833-838, vol. 6, No. 7, Bioorganic & Medicinal Chemistry Letters.
Ganellin et al,. “Structure-activity studies with histamine H3-receptor ligands”, 1995, pp. 455-468, vol. 36. No. 3, Ars. Pharmaceutica.
Kathmann et al, “Intermediate affinity and potency of clozapine and low affinity of other neuroleptics and of antidepressants at H3receptors”, 1994, pp. 464-468, vol. 116, Psychopharmacology.
Plazzi et al, “Heteroarylaminoethyl and heteroarylthioethyl imidazoles. Synthesis and H3-receptor affinity”, 1995, pp. 881-889, vol. 30, Eur. J. Med. Chem.
Schwartz et al, “A third histamine receptor subtype: Characterisation, localization and functions of the H3-receptor”, 1990, pp. 13-23, vol. 30, Agents and Actions.
Schwartz et al, “Histaminergic Transmission in the Mammalian Brain”, Jan. 1991, pp. 1-51, vol. 71, No. 1, Physiological Reviews.
Stark et al, “Developments of histamine H3-receptor antagonists”, 1996, pp. 507-520, vol. 21, No. 5, Drugs of the Future.
Wolin et al, “Novel H3Receptor Antagonists Sulfonamide Homologs of Histamine”, 1998, pp. 2157-2162, Bioorganic & Medicinal Chemistry Letters 8.
Bertrand Isabelle
Capet Marc
Labeeuw Olivier
Lecomte Jeanne-Marie
Levoin Nicolas
Anderson Rebecca
Bioprojet
Otton Alicia L
Schulman, Esq. B. Aaron
Stites & Harbison PLLC
LandOfFree
Histamine H3-receptor ligands and their therapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Histamine H3-receptor ligands and their therapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histamine H3-receptor ligands and their therapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4295549